Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Q4 Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd0030Ia&default-theme=true

RNS Number : 0030I  Benchmark Holdings PLC  30 November 2022

30 November 2022

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

Q4 Results

(3 months ended 30 September 2022)

 

Strong end to FY22 continuing track record of consistent delivery

 

In compliance with the terms of the Company's unsecured green bond which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the 3
months ended 30 September 2022 (the "period"). All Q4FY22 and Q4FY21 figures
quoted in this announcement are based on unaudited accounts.

 

This morning the Company published its full year audited results for the 12
months ended 30 September 2022 which can be found
on https://www.benchmarkplc.com/investors
(https://www.benchmarkplc.com/investors) .

 

Highlights - strong end to the year

·      Revenues £42.8m, 15% ahead of the prior year (+6% CER) with
growth across all business areas:

o  Genetics - revenues 15% above Q4 2021 (+11% CER) driven by higher sales of
salmon eggs

o  Advanced Nutrition - revenues 10% above the prior year (-6% CER) driven by
commercial focus and continued innovation

o  Health - revenues +31% above Q4 2021 (+31% CER) driven by increased sales
of Ectosan(â) Vet and CleanTreat(â)

·      Adjusted EBITDA of £8.8m, 23% ahead of last year driven by
higher sales, operational efficiencies and continued financial discipline

·      Adjusted EBITDA excluding fair value movements from biological
assets 57% ahead

·      Refinancing of NOK850m secured bond through the issue of a
NOK750m unsecured green bond

·      Post period end, refinancing of $15m RCF with a £20m RCF
expiring in June 2025

·      Cash of £35.1m and Liquidity of c £51.1m (cash and available
facility) as at 29th November 2022

 

 £m                                                Q4 FY22  Q4 FY21  % AER  % CER(**)  FY22          FY21

                                                                                       (full year)
 Revenue                                           42.8     37.3     15%    6%         158.3         125.1
 Adjusted
 Adjusted EBITDA(1)                                8.8      7.1      23%    15%        31.2          19.4
 Adj. EBITDA excluding biological asset movements  9.6      6.1      57%    48%        29.6          16.1
 Adjusted Operating Profit(2)                      3.5      3.5      0%     -9%        9.1           10.8
 Statutory
 Operating (loss)/profit                           (1.7)    0.5      -460%  -524%      (7.9)         (5.4)
 Loss before tax                                   (6.8)    (3.2)    -109%  -127%      (23.2)        (9.2)
 Loss for the Period                               (8.9)    (5.7)    -56%   -58%       (30.5)        (11.6)
 Basic loss per share (p)                          (1.36)   (0.91)                     (4.60)        (1.93)
 Net debt(3)                                       (73.7)   (80.9)                     (73.7)        (80.9)
 Net debt excluding lease liabilities              (47.5)   (56.9)                     (47.5)        (56.9)

 

**  Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

Business Area Summary

 £m                                                              Q4 FY22  Q4 FY21  % AER  % CER(**)  FY22          FY21

                                                                                                     (full year)
 Revenue
 Advanced Nutrition                                              18.9     17.1     10%    -6%        80.3          70.5
 Genetics                                                        18.3     15.9     15%    11%        58.0          46.8
 Health                                                          5.6      4.3      31%    31%        20.1          7.8
 Adjusted EBITDA(1)
 Advanced Nutrition                                              4.7      3.6      29%    8%         19.0          13.8
 Genetics                                                        5.5      3.3      65%    72%        16.0          11.5
 -       Net of fair value movements in biological assets        6.3      2.3      173%   183%       14.4          8.2
 Health                                                          0.6      1.1      -43%   -45%       0.1           (2.7)

**  Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

 

Operational highlights

·      Opening of new salmon egg incubation centre in Iceland

·      Salmon egg capacity in Norway and Iceland sold out

·      Progress in commercialisation of SPR shrimp - client wins in
Indonesia and Vietnam

·      Continued positive commercial momentum in Advanced Nutrition and
focus on operational optimisation

·      Increased customer use and adoption of Ectosan® Vet and
CleanTreat®

 

Current trading and outlook - good momentum in line with our expectations

·       Good start to the year and positive momentum in the business

·       Diversified business and proactive commercial approach create
resilience to ongoing macroeconomic pressures

·       Recently announced change in tax regime for aquaculture
producers in Norway expected to have a marginal direct effect

·       Continue to progress towards a dual listing on Euronext Growth
Oslo with intention to uplist to the Oslo Børs in H1 2023

 

Enquiries

 

 For further information, please contact:
 Benchmark Holdings plc                                       Tel:  020 3696 0630
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                                     Tel:  020 7260 1000
 James Black, Freddie Barnfield, Duncan Monteith

 MHP                                                          Tel:  020 3128 8004
 Katie Hunt, Reg Hoare, Veronica Farah                        benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

 

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia, in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

 

Management Report

 

The Group reported a strong Q4, continuing the good performance delivered
throughout the year. Group revenues at £42.8m were 15% ahead of the prior
year (+6% CER) reflecting good trading across all business areas despite the
ongoing macroeconomic challenges and price pressure in some of our end
markets. Our three business areas delivered revenue growth, with Advanced
Nutrition growing by 10%, Genetics by 15% and Health by 31%. Advanced
Nutrition continued to capitalise on its renewed commercial focus, Genetics
benefitted from peak demand for its specialist salmon eggs and in Health our
growth reflects the increased customer uptake of our sea lice solution
Ectosan(â) Vet and CleanTreat(â).

 

Operating costs in Q4 2022 were 30% higher at £13.3m (Q4 2021: £10.2m)
driven by higher activity levels and a strong dollar in the quarter.  The
increase was 21% at constant exchange rates.  R&D expenses were £2.0m,
10% up driven by small increases in Health and Genetics with R&D spend in
Advanced Nutrition remaining flat against the prior year.

 

Adjusted EBITDA from continuing operations for the quarter was £8.8m, 23%
ahead of the prior year (Q4FY21: £7.1m) reflecting increased sales,
operational leverage and financial discipline. Excluding fair value movements
from biological assets, Adjusted EBITDA was £9.6m, 57% ahead of the prior
year.

 

As noted in our full year announcement released today, our net result was
impacted by an increased depreciation charge associated with the leases on the
vessels for our CleanTreat® operation, and higher finance costs due to a
higher interest charge and costs associated with movements of hedging
instruments as well as costs associated with the refinancing of our NOK bond.

 

Advanced Nutrition

 

Revenues from Advanced Nutrition were £18.9m, up 10% (-6% CER). By product
area Artemia sales were up 5%, Diets up 20% and sales from Health products
increased by 25% compared to the same period last year.  The gross profit
margin grew slightly from 60% to 61%.

 

Operating costs and R&D totalled £6.8m, up 10% compared to the prior
year. Continued cost discipline and operational improvements resulted in an
increase in Adjusted EBITDA of 29% (+8% CER) to £4.7m. As a result, the
Adjusted EBITDA margin reached 25% (Q4FY21:21%).

 

Genetics

 

Genetics performed well in the period with revenues of £18.3m, 15% above the
prior year (Q4 2021: £15.9m) driven by higher sales of salmon eggs resulting
in all of our capacity in our Norway and Iceland facilities being sold out.
Harvest revenues were also higher, and we benefitted from first commercial
revenues of our SPR shrimp compared to last year.  The gross profit margin
was 55% (Q4FY21: 42%)

 

Adjusted EBITDA of £5.5m in the period was 65% higher than the prior year (Q4
2021: £3.3m) primarily from higher sales together with cost discipline
resulting in operational leverage. Excluding the fair value movements from
biological assets Adjusted EBITDA was £6.3m, 173% ahead of the prior year (Q4
FY21: £2.3m).  As a result, the Adjusted EBITDA margin excluding biological
asset movements was 35% (Q4 FY21: 15%).

 

By species, salmon delivered an excellent performance benefitting from peak
demand for our biosecure, specialist eggs available year round and capacity
and quality enhancements from our new incubation centre in Iceland.  In
shrimp, we continued to progress in our commercialisation of our recently
launched SPR shrimps with client wins in Indonesia and Vietnam. We continue to
work on developing our product range to the specific needs of the key shrimp
markets.

 

Health

 

Health delivered a good performance in Q4, reflecting increased use and
adoption of our sea lice solution Ectosan Vet and CleanTreat. Revenues in the
quarter were £5.6m, up 30% reflecting progress in use and adoption of our
solution.  Adjusted EBITDA in the period was £0.6m (Q4FY21: £1.1m). This
reflects the costs associated with having two CleanTreat® units in operation
against one in the same period last year.   Operating costs and R&D were
£1.9m in the period (Q4 FY21: £1.5m).  Costs associated with the leases of
the vessels for the CleanTreat units amounted to £1.8m.

 

Finance costs, cashflow and net debt

 

During the quarter, the existing NOK 850m was refinanced through the issue of
an unsecured NOK 750m green bond with a maturity date in September 2025 and is
to be listed on the Oslo Stock Exchange. The company also extended and
increased its RCF facility from $15m to £20m with maturity in June 2025.

 

Net finance cost for the quarter of £5.1m was higher than the prior year (Q4
2021: £3.7m).  Movements in the quarter in the fair value of our financial
instruments taken out to hedge our external borrowings caused a charge of
£5.3m, (Q4 2021: charge of £0.4m).  Interest charges for the period of
£5.3m (Q4 2021: £1.9m) included one-off early bond settlement fees of £1.6m
and accelerated amortisation of previously deferred borrowing fees of £0.9m
following the refinancing of the old bond.  These charges were offset in the
quarter by foreign exchange gains of £5.6m (Q4 2021: loss £1.2m) due to
movements in exchange rates towards the end of the year.

 

Positive operating cashflows from strong trading in the quarter, together with
repayment of some of the borrowings in the refinancing exercise, left net debt
at the quarter end at £73.7m (30 June 2022: £89.1m; 30 Sept 2021:
£80.9m).  Net debt excluding lease liabilities was £47.5m (30 June 2022:
£59.3m; 30 Sept 2021: £56.9m).

 

 

Outlook

 

We have had a good start to the year and there is good momentum in the
business. Cost inflation and other macroeconomic pressures will continue to be
a feature across the world in 2023 and we are not immune. However, we have a
well-diversified, balanced business which creates resilience to challenges in
individual markets as well as opportunities. In addition, we will continue to
proactively mitigate potential pressure on our business and our margins
through pricing, supplier management and operational improvements. The
recently announced change in the tax regime for aquaculture producers in
Norway is expected to have a marginal direct effect on our business.

 

Looking further into the future, Benchmark is uniquely positioned in an
industry that is structurally growing and driven by multiple megatrends. This
creates significant opportunity for growth and increasing returns for
shareholders in the near and medium term and for many years to come.

 

 

Consolidated Income Statement for the period ended 30 September 2022

 

 All figures in £000's                                                Notes  Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Revenue                                                              4      42,758        37,261        158,277     125,062
 Cost of sales                                                               (18,625)      (17,831)      (75,149)    (59,477)
 Gross profit                                                                24,133        19,430        83,128      65,585
 Research and development costs                                              (2,028)       (1,838)       (6,691)     (7,010)
 Other operating costs                                                       (13,290)      (10,195)      (44,661)    (38,221)
 Share of loss of equity-accounted investees, net of tax                     (57)          (299)         (595)       (905)
 Adjusted EBITDA²                                                            8,758         7,098         31,181      19,449
 Exceptional - restructuring, disposal and acquisition related items  5      (423)         871           16          (184)
 EBITDA¹                                                                     8,335         7,969         31,197      19,265
 Depreciation and impairment                                                 (4,639)       (3,309)       (19,897)    (8,359)
 Amortisation and impairment                                                 (5,440)       (4,174)       (19,161)    (16,283)
 Operating (loss)/profit                                                     (1,744)       486           (7,861)     (5,377)
 Finance cost                                                                (11,547)      (3,771)       (20,057)    (7,987)
 Finance income                                                              6,496         40            4,741       4,185
 Loss before taxation                                                        (6,795)       (3,245)       (23,177)    (9,179)
 Tax on loss                                                          6      (2,074)       (2,455)       (7,274)     (2,397)
 Loss for the period                                                         (8,869)       (5,700)       (30,451)    (11,576)
 Loss for the period attributable to:
 - Owners of the parent                                                      (9,561)       (6,101)       (32,087)    (12,891)
 - Non-controlling interest                                                  692           401           1,636       1,315
                                                                             (8,869)       (5,700)       (30,451)    (11,576)

 Earnings per share
 Basic loss per share (pence)                                         7      (1.36)        (0.91)        (4.60)      (1.93)
 Diluted loss per share (pence)                                       7      (1.36)        (0.91)        (4.60)      (1.93)

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items

 

Consolidated Statement of Comprehensive Income for the period ended 30
September 2022

 

 All figures in £000's                                                     Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)

 Loss for the period                                                       (8,869)       (5,700)       (30,451)    (11,576)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                  23,225        4,113         47,606      (9,929)
 Cash flow hedges - changes in fair value                                  2,047         760           2,627       3,054
 Cash flow hedges - reclassified to profit or loss                         2,387         164           2,546       709
 Total comprehensive income for the period                                 18,790        (663)         22,328      (17,742)

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                    18,109        (1,026)       20,326      (19,329)
 - Non-controlling interest                                                681           363           2,002       1,587
                                                                           18,790        (663)         22,328      (17,742)

 

The accompanying notes are an integral part of this consolidated financial
information.

 

Consolidated Balance Sheet as at 30 September 2022

 

 

                                                                          30 September 2022  30 September 2021
 All figures in £000's                                             Notes  (audited)          (audited)
 Assets
 Property, plant and equipment                                            81,900             78,780
 Right-of-use assets                                                      27,034             25,531
 Intangible assets                                                        245,264            229,040
 Equity-accounted investees                                               3,113              3,354
 Other investments                                                        15                 15
 Biological and agricultural assets                                       20,878             21,244
 Non-current assets                                                       378,204            357,964
 Inventories                                                              29,813             20,947
 Biological and agricultural assets                                       25,780             17,121
 Trade and other receivables                                              56,377             46,498
 Cash and cash equivalents                                                36,399             39,460
 Current assets                                                           148,369            124,026
 Total assets                                                             526,573            481,990
 Liabilities
 Trade and other payables                                                 (44,324)           (46,668)
 Loans and borrowings                                              8      (17,091)           (10,654)
 Corporation tax liability                                                (10,211)           (5,634)
 Provisions                                                               (1,631)            (563)
 Current liabilities                                                      (73,257)           (63,519)
 Loans and borrowings                                              8      (93,045)           (109,737)
 Other payables                                                           (8,996)            (911)
 Deferred tax                                                             (27,990)           (28,224)
 Non-current liabilities                                                  (130,031)          (138,872)
 Total liabilities                                                        (203,288)          (202,391)
 Net assets                                                               323,285            279,599
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     9      704                670
 Additional paid-in share capital                                  9      420,824            400,682
 Capital redemption reserve                                               5                  5
 Retained earnings                                                        (185,136)          (154,231)
 Hedging reserve                                                          (703)              (5,876)
 Foreign exchange reserve                                                 77,705             30,465
 Equity attributable to owners of the parent                              313,399            271,715
 Non-controlling interest                                                 9,886              7,884
 Total equity and reserves                                                323,285            279,599

 

The accompanying notes are an integral part of this consolidated financial
information.

 

Consolidated Statement of Changes in Equity for the period ended 30 September
2022

 

 

                                                      Share     Additional paid-in share capital*      Other      Hedging      Retained     Total attributable       Non-          Total

capital
reserves
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                      £000      £000                                   £000       £000         £000         £000                     £000          £000

 As at 1 October 2021 (audited)                      670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income for the period
 (Loss) for the period                               -         -                                      -          -            (32,087)     (32,087)                 1,636         (30,451)
 Other comprehensive income                          -         -                                      47,240     5,173        -            52,413                   366           52,779
 Total comprehensive income for the period           -         -                                      47,240     5,173        (32,087)     20,326                   2,002         22,328

 Contributions by and distributions to owners
 Share issue                                         34        20,704                                 -          -            -            20,738                   -             20,738
 Share issue costs recognised through equity         -         (562)                                  -          -            -            (562)                    -             (562)
 Share-based payment                                 -         -                                      -          -            1,182        1,182                    -             1,182
 Total contributions by and distributions to owners  34        20,142                                 -          -            1,182        21,358                   -             21,358

 Changes in ownership
 Total changes in ownership interests                -         -                                      -          -            -            -                        -             -
 Total transactions with owners of the Company       34        20,142                                 -          -            1,182        21,358                   -             21,358
 As at 30 September 2022 (audited)                   704       420,824                                77,710     (703)        (185,136)    313,399                  9,886         323,285

 As at 1 October 2020 (audited)                      668       399,601                                40,683     (9,651)      (142,170)    289,131                  6,309         295,440
 Comprehensive income for the period
 (Loss) for the period                               -         -                                      -          -            (12,891)     (12,891)                 1,315         (11,576)
 Other comprehensive income                          -         -                                      (10,213)   3,775        -            (6,438)                  272           (6,166)
 Total comprehensive income for the period           -         -                                      (10,213)   3,775        (12,891)     (19,329)                 1,587         (17,742)

 Contributions by and distributions to owners
 Share issue                                         2         1,081                                  -          -            -            1,083                    -             1,083
 Share issue costs recognised through equity         -         -                                      -          -            -            -                        -             -
 Share-based payment                                 -         -                                      -          -            830          830                      -             830
 Total contributions by and distributions to owners  2         1,081                                  -          -            830          1,913                    -             1,913

 Changes in ownership
 Acquisition of NCI                                  -         -                                      -          -            -            -                        (12)          (12)
 Total changes in ownership interests                -         -                                      -          -            -            -                        (12)          (12)
 Total transactions with owners of the Company       2         1,081                                  -          -            830          1,913                    (12)          1,901
 As at 30 September 2021 (audited)                   670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.

 

 

Consolidated Statement of Cash Flows for the period ended 30 September 2022

 

                                                                FY 2022 (audited)  FY 2021 (audited)

                                                                £000               £000
 Cash flows from operating activities
 Loss for the period                                            (30,451)           (11,576)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment   8,602              5,017
 Depreciation and impairment of right-of-use assets             11,295             3,342
 Amortisation and impairment of intangible fixed assets         19,161             16,283
 Loss on sale of property, plant and equipment                  (43)               46
 Finance income                                                 (319)              (1,442)
 Finance costs                                                  18,437             7,987
 Increase in fair value of contingent consideration receivable  (1,203)            -
 Share of loss of equity-accounted investees, net of tax        595                905
 Foreign exchange losses                                        (3,985)            (1,800)
 Share-based payment expense                                    1,182              830
 Other adjustments for non-cash items                           (276)              -
 Tax credit                                                     7,274              2,397
 Increase in trade and other receivables                        (8,511)            (8,178)
 Increase in inventories                                        (5,406)            (3,554)
 Increase in biological and agricultural assets                 (6,099)            (5,427)
 Increase in trade and other payables                           6,946              5,547
 Increase in provisions                                         1,058              -
                                                                18,257             10,377
 Income taxes paid                                              (7,447)            (4,587)
 Net cash flows generated from operating activities             10,810             5,790
 Investing activities
 Purchase of investments                                        (378)              (578)
 Receipts from disposal of investments                          1,544              9
 Purchases of property, plant and equipment                     (10,808)           (17,683)
 Purchase of intangibles                                        (205)              (5,038)
 Capitalised research and development costs                     (1,708)            -
 Proceeds from sale of fixed assets                             220                112
 Interest received                                              119                88
 Net cash flows used in investing activities                    (11,216)           (23,090)
 Financing activities
 Proceeds of share issues                                       20,737             750
 Share-issue costs recognised through equity                    (562)              -
 Acquisition of NCI                                             -                  (12)
 Proceeds from bank or other borrowings                         67,939             -
 Repayment of bank or other borrowings                          (74,874)           (3,106)
 Interest and finance charges paid                              (9,629)            (7,699)
 Repayments of lease liabilities                                (10,533)           (4,602)
 Net cash outflow from financing activities                     (6,922)            (14,669)
 Net decrease in cash and cash equivalents                      (7,328)            (31,969)
 Cash and cash equivalents at beginning of period               39,460             71,605
 Effect of movements in exchange rate                           4,267              (176)
 Cash and cash equivalents at end of period                     36,399             39,460

 

 

Unaudited notes to the quarterly financial statements for the period ended 30
September 2022

 

 

1. Basis of preparation

Benchmark Holdings plc (the 'Company') is a company incorporated domiciled in
the United Kingdom. These consolidated quarterly financial statements as at
and for the three months and year ended 30 September 2022 represents that of
the Company and its subsidiaries (together referred to as the 'Group').

 

These quarterly financial statements have been prepared in accordance with IAS
34 Interim Financial Reporting and should be read in conjunction with the
Group's consolidated financial statements as at and for the year ended 30
September 2022. They do not include all the information required for a
complete set of IFRS financial statements.  However, selected explanatory
notes are included to explain events and transactions that are significant to
an understanding of the changes in the Group's financial position and
performance since the last annual financial statements.  Statutory accounts
for the year ended 30 September 2022 were approved by the Directors on 30
November 2022 and will be delivered to the Registrar of Companies after the
AGM on 16 February 2023.  The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 30 September 2022 the Group had net assets of £323.3m (30 September
2021: £279.6m), including cash of £36.4m (30 September 2021: £39.5m) as
set out in the consolidated balance sheet. The Group made a loss for the year
of £30.5m (year ended 30 September 2021: loss £11.6m).

 

As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.

 

The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced with the agreement of a
new GBP20m RCF on 21 November 2022 with a maturity of June 2025 maturity.
Furthermore, our NOK 216m loan facility (which had NOK 165.6m outstanding at
the year end) which was set to mature in October 2023 was combined with our
NOK 17.5m overdraft facility into a new loan facility of NOK 179.5m on 1
November 2022, with a new maturity date in a further 5 years no later than 15
January 2028. Following all of these refinancing transactions, the Directors
are satisfied there are sufficient facilities in place during the assessment
period.

 

The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants.

 

The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.

 

1.     Basis of preparation (continued)

 

These financial statements have been prepared in accordance with international
accounting standards in conformity with the requirements of the Companies Act
2006 and International Financial Reporting Standards adopted pursuant to
Regulation (EC) No 1606/2002 as it applies in the European Union.

 

The preparation of financial statements in compliance with adopted IFRSs
requires the use of certain critical accounting estimates. It also requires
Group management to exercise judgement in applying the Group's accounting
policies. The areas where significant judgements and estimates have been made
in preparing the financial statements and their effect are disclosed in Note
2.

 

2.     Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2022.

 

3.     Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health - the segment provides health products and services to the
global aquaculture market.

3.     Segment information (continued)

 

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

Reconciliations of segmental information to IFRS measures

 

 Segmental Revenue
 All figures in £000's         Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Genetics                     18,314        15,932        58,008      46,797
 Advanced Nutrition           18,872        17,093        80,286      70,530
 Health                       5,602         4,269         20,135      7,832
 Corporate                    902           1,209         5,120       4,820
 Inter-segment sales          (932)         (1,242)       (5,272)     (4,917)
 Total                        42,758        37,261        158,277     125,062

  Segmental Adjusted EBITDA
 All figures in £000's         Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Genetics                     5,473         3,309         15,980      11,528
 Advanced Nutrition           4,706         3,644         19,017      13,802
 Health                       625           1,104         108         (2,685)
 Corporate                    (2,046)       (959)         (3,924)     (3,196)
 Total                        8,758         7,098         31,181      19,449

 

 

  Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
 All figures in £000's                                                 Q4 2022                   Q4 2021                   FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Total reportable segment Adjusted EBITDA                             10,804                    8,057                     35,105      22,645
 Corporate Adjusted EBITDA                                            (2,046)                   (959)                     (3,924)     (3,196)
 Adjusted EBITDA                                                      8,758                     7,098                     31,181      19,449
 Exceptional - restructuring, disposal and acquisition related items  (423)                     871                       16          (184)
 Depreciation and impairment                                          (4,639)                   (3,309)                   (19,897)    (8,359)
 Amortisation and impairment                                          (5,440)                   (4,174)                   (19,161)    (16,283)
 Net finance costs                                                    (5,051)                   (3,731)                   (15,316)    (3,802)
 Loss before taxation                                                 (6,795)                   (3,245)                   (23,177)    (9,179)

 

 

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.

 

Disaggregation of revenue

 

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

 

Sale of goods and provision of services

                         3 months ended 30 September 2022 (unaudited)
 All figures in £000's   Genetics    Advanced Nutrition    Health     Corporate    Inter-segment sales    Total
 Sale of goods           17,449      18,852                4,085      -            -                      40,386
 Provision of services   855         -                     1,517      -            -                      2,372
 Inter-segment sales     10          20                    -          902          (932)                  -
                         18,314      18,872                5,602      902          (932)                  42,758

                         3 months ended 30 September 2021 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Sale of goods           14,925      17,077                2,593      -            -                      34,595
 Provision of services   990         -                     1,676      -            -                      2,666
 Inter-segment sales     17          16                    -          1,209        (1,242)                -
                         15,932      17,093                4,269      1,209        (1,242)                37,261

                         12 months ended 30 September 2022 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Sale of goods           53,978      80,191                13,528     -            -                      147,697
 Provision of services   3,973       -                     6,607      -            -                      10,580
 Inter-segment sales     57          95                    -          5,120        (5,272)                -
                         58,008      80,286                20,135     5,120        (5,272)                158,277

                         12 months ended 30 September 2021 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Sale of goods           41,947      70,458                6,135      -            -                      118,540
 Provision of services   4,825       -                     1,697      -            -                      6,522
 Inter-segment sales     25          72                    -          4,820        (4,917)                -
                         46,797      70,530                7,832      4,820        (4,917)                125,062

 

4.     Revenue (continued)

 Sale of goods and provision of services (continued)

 Primary geographical markets

                         3 months ended 30 September 2022 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Norway                  11,151      314                   4,204      -            -                      15,669
 India                   38          1,074                 -          -            -                      1,112
 Singapore               -           121                   -          -            -                      121
 Turkey                  -           1,314                 -          -            -                      1,314
 Ecuador                 -           2,606                 -          -            -                      2,606
 Greece                  -           931                   -          -            -                      931
 Faroe Islands           1,539       2                     209        -            -                      1,750
 UK                      1,099       26                    33         -            -                      1,158
 Chile                   237         8                     222        -            -                      467
 Rest of Europe          2,158       844                   -          -            -                      3,002
 Rest of World           2,082       11,612                934        -            -                      14,628
 Inter-segment sales     10          20                    -          902          (932)                  -
                         18,314      18,872                5,602      902          (932)                  42,758

                         3 months ended 30 September 2021 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Norway                  10,526      135                   2,898      -            -                      13,559
 India                   -           3,029                 -          -            -                      3,029
 Singapore               -           1,954                 -          -            -                      1,954
 Greece                  -           986                   -          -            -                      986
 Faroe Islands           1,171       2                     180        -            -                      1,353
 Turkey                  -           1,109                 -          -            -                      1,109
 UK                      276         20                    145        -            -                      441
 Ecuador                 -           1,057                 -          -            -                      1,057
 Chile                   400         1                     296        -            -                      697
 Rest of Europe          2,347       763                   -          -            -                      3,110
 Rest of World           1,195       8,021                 750        -            -                      9,966
 Inter-segment sales     17          16                    -          1,209        (1,242)                -
                         15,932      17,093                4,269      1,209        (1,242)                37,261

 

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         12 months ended 30 September 2022 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Norway                  34,666      965                   15,571     -            -                      51,202
 India                   619         12,001                -          -            -                      12,620
 Singapore               -           7,044                 -          -            -                      7,044
 Turkey                  -           6,419                 -          -            -                      6,419
 Ecuador                 18          6,472                 -          -            -                      6,490
 Greece                  2           6,197                 -          -            -                      6,199
 Faroe Islands           5,465       9                     587        -            -                      6,061
 UK                      4,318       93                    199        -            -                      4,610
 Chile                   1,006       15                    871        -            -                      1,892
 Rest of Europe          7,110       4,056                 -          -            -                      11,166
 Rest of World           4,747       36,920                2,907      -            -                      44,574
 Inter-segment sales     57          95                    -          5,120        (5,272)                -
                         58,008      80,286                20,135     5,120        (5,272)                158,277

                         12 months ended 30 September 2021 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
 Norway                  27,129      570                   3,689      -            -                      31,388
 India                   -           12,166                3          -            -                      12,169
 Singapore               -           7,544                 -          -            -                      7,544
 Greece                  25          6,108                 -          -            -                      6,133
 Faroe Islands           5,636       18                    348        -            -                      6,002
 Turkey                  -           5,977                 -          -            -                      5,977
 UK                      3,843       117                   622        -            -                      4,582
 Ecuador                 -           4,066                 -          -            -                      4,066
 Chile                   437         7                     2,335      -            -                      2,779
 Rest of Europe          6,922       4,208                 26         -            -                      11,156
 Rest of World           2,780       29,677                809        -            -                      33,266
 Inter-segment sales     25          72                    -          4,820        (4,917)                -
                         46,797      70,530                7,832      4,820        (4,917)                125,062

 

 

5.     Exceptional - restructuring, disposal, and acquisition related
items

 

Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 

 All figures in £000's              Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Acquisition related items          -             (850)         -           (850)
 Exceptional restructuring costs    1,668         110           1,229       480
 Cost in relation to disposals      (1,245)       (131)         (1,245)     554
 Total exceptional items            423           (871)         (16)        184

 

Acquisition-related items are costs incurred in investigating and acquiring
new businesses. In 2021 contingent consideration of £850,000 was released in
relation to the purchase of Benchmark Genetics (USA) Inc.

 

Exceptional costs include: £843,000 (2021: £nil) of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £276,000 (2021: £480,000) relating to restructuring costs.

 

Costs in relation to disposals includes a credit of £1,203,000 (2021: £nil)
in relation to additional contingent consideration received and receivable
from disposals in previous years (£294,000 relating to the disposal of
Aquaculture UK on 7 February 2020, and £909,000 relating to the disposal of
Improve International Limited and its subsidiaries on 23 June 2020) together
with legal fees, lease costs and disposal items (net of proceeds received)
totaling £42,000 relating to additional costs and disposals proceeds relating
to disposals that occurred in 2020.

 

6.     Taxation

 All figures in £000's                                     Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      4,124         2,716         11,727      5,383
 Adjustment in respect of prior periods                    (39)          502           (39)        502
 Total current tax charge                                  4,085         3,218         11,688      5,885

 Deferred tax:
 Origination and reversal of temporary differences         (2,011)       (768)         (4,414)     (3,228)
 Deferred tax movements in respect of prior periods        -             5             -           (260)
 Total deferred tax credit                                 (2,011)       (763)         (4,414)     (3,488)

 Total tax charge                                          2,074         2,455         7,274       2,397

 

 

7.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

 

                                                            Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Loss attributable to equity holders of the parent (£000)   (9,561)       (6,101)       (32,087)    (12,891)
 Weighted average number of shares in issue (thousands)     703,961       670,141       698,233     669,459
 Basic loss per share (pence)                               (1.36)        (0.91)        (4.60)      (1.93)

 

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 6,240,304 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2021: 4,615,712). These potential ordinary shares could dilute earnings/loss
per share in the future.

8.     Loans and borrowings

 All figures in £000's             FY 2022     FY 2021

(audited)
(audited)
 Non-Current
 2025 750m NOK Loan notes          61,054      -
 2023 850m NOK Loan notes          -           75,478
 Bank borrowings                   17,226      19,314
 Lease liabilities                 14,765      14,945
                                   93,045      109,737
 Current
 Bank borrowings                   5,569       1,612
 Lease liabilities                 11,522      9,042
                                   17,091      10,654
 Total loans and borrowings        110,136     120,391

 

At 30 September 2022 the fair value of the unsecured floating rate listed
green bond of NOK 750m was not materially different to the nominal value and
has not been separately disclosed. At 30 September 2021 the fair value of 2023
850m NOK Loan notes was £73,981,000.

 

On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay the NOK 850m floating rate listed bond, originally raised in
June 2019.

 

A USD 15m Revolving Credit Facility ("RCF") has been provided by DNB Bank ASA
(50%) and HSBC UK Bank PLC (50%). At 30 September 2022 £4,000,000 was drawn
on this facility. The facility was undrawn at 30 September 2021.

 

8.   Loans and borrowings (continued)

 

Benchmark Genetics Salten AS (formerly SalmoBreed Salten AS) had the following
loans (which are ring-fenced debt without recourse to the remainder of the
Group) at 30 September 2022:

-       Term loan with a balance of NOK 165.6m (2021: NOK 180.0m)
provided by Nordea Bank Norge Abp. The loan is a five-year term loan ending
November 2023 at an interest rate of 2.5% above three-month NIBOR.

-       NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2022 (2021: undrawn).

-       An additional NOK 17.5m overdraft facility was provided by
Nordea Bank Norge Abp during the year with maturity in December 2022. This
facility was undrawn at 30 September 2022.

-       Term loan with a balance of NOK 40.1m (2021: NOK 44.7m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2022 was 4.95%. The
interest rate on this loan is variable.

-       NOK 21.75m loan provided by Salten Aqua ASA (the minority
shareholder). The loan attracts interest at 2.5% above three-month NIBOR and
is repayable on maturity of the Nordea term loan above.

 

Subsequent to the year end on 1 November 2022, the Nordea Bank term loan above
was refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms remain the same.

 

Furthermore on 21 November 2022, the Group refinanced the USD15m RCF with a
secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The
margin on this facility is a minimum of 2.75% and a maximum of 3.25%,
dependent upon the leverage of the Group above the relevant risk free
reference or IBOR rates depending on which currency is drawn.

 

The lease liabilities are secured on the assets to which they relate.

 

9.     Share capital and additional paid-in share capital

                                               Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid                         £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2021                  670,374,484  670            400,682
 Shares issued through placing and open offer  33,401,620   34             20,069
 Exercise of share options                     184,694      -              73
 Balance at 30 September 2022                  703,960,798  704            420,824

 

During the year ended 30 September 2022, the Group issued a total 184,694
ordinary shares of 0.1p each to certain employees of the Group relating to
share options of which 12,509 were exercised at a price of 0.1 pence, and
172,185 were exercised at a price of 42.5p.

 

On 29 November 2021, the Company issued 33,401,620 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 62.0
pence per share. Gross proceeds of £20.7m were received for the placing and
subscription shares. Non-recurring costs of £0.6m were in relation to the
share issues and this has been charged to the share premium account (presented
within Additional paid-in share capital).

 

During the year ended 30 September 2021, the Group issued a total of 2,152,600
ordinary shares of 0.1p each to certain employees of the Group relating to
share options, of which 426,182 were exercised at a price of 0.1 pence,
1,626,436 were exercised at a price of 42.5 pence and 99,982 were exercised at
a price of 58.5 pence.

 

During the prior year, contingent consideration totalling USD 450,000
(£333,000) became payable following the acquisition of aquaculture breeding
programmes centred on shrimp from Centro de Investigación de la Acuicultura
de Colombia Ceniacua on 11 August 2016. At the Group's discretion, the
contingent consideration was paid in ordinary shares in the Group and the
Group therefore issued 536,272 ordinary shares of 0.1p each on 13 January 2021
to settle this liability.

 

 

10.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
including acquisition related items and is shown on the Income Statement.

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

Adjusted Operating Profit is operating loss before exceptional items including
acquisition related items and amortisation and impairment of intangible assets
excluding development costs as reconciled below.

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items
including acquisition related items as reconciled below. These measures are
not defined performance measures in IFRS. The Group's definition of these
measures may not be comparable with similarly titled performance measures and
disclosures by other entities.

 

Reconciliation of Adjusted Operating Profit to Operating Loss

 All figures in £000's                                                             Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Revenue                                                                           42,758        37,261        158,277     125,062
 Cost of sales                                                                     (18,625)      (17,831)      (75,149)    (59,477)
 Gross profit                                                                      24,133        19,430        83,128      65,585
 Research and development costs                                                    (2,028)       (1,838)       (6,691)     (7,010)
 Other operating costs                                                             (13,290)      (10,195)      (44,661)    (38,221)
 Depreciation and impairment                                                       (4,639)       (3,309)       (19,897)    (8,359)
 Amortisation of capitalised development costs                                     (615)         (299)         (2,165)     (299)
 Share of loss of equity accounted investees net of tax                            (57)          (299)         (595)       (905)
 Adjusted operating profit                                                         3,504         3,490         9,119       10,791
 Exceptional - restructuring, disposal and acquisition related items               (423)         871           16          (184)
 Amortisation and impairment of intangible assets excluding development costs      (4,825)       (3,875)       (16,996)    (15,984)
 Operating (loss)/profit                                                           (1,744)       486           (7,861)     (5,377)

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 

 All figures in £000's                                                             Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)

 Loss before taxation                                                              (6,795)       (3,245)       (23,177)    (9,179)
 Exceptional - restructuring, disposal and acquisition related items               423           (871)         (16)        184
 Amortisation and impairment of intangible assets excluding development costs      4,825         3,875         16,996      15,984
 Adjusted (loss)/profit before tax                                                 (1,547)       (241)         (6,197)     6,989

 

 

10.  Alternative performance measures and other metrics (continued)

 

Other
Metrics

 

 All figures in £000's                       Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Total R&D Investment
 Research and development costs              2,028         1,838         6,691       7,010
 Internal capitalised development costs      112           1,351         1,708       4,813
 Total R&D investment                        2,140         3,189         8,399       11,823

 

 

 All figures in £000's                                                                                    Q4 2022       Q4 2021       FY 2022     FY 2021

(unaudited)
(unaudited)
(audited)
(audited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                                                         8,758         7,098         31,181      19,449
 Exclude fair value movement                                                                             848           (996)         (1,595)     (3,323)
 Adjusted EBITDA excluding fair value movement in biological assets                                      9,606         6,102         29,586      16,126      16,126

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

                              30 September 2022
 All figures in £000's        (audited)
 Cash and cash equivalents    36,399
 Undrawn bank facility        9,398
                              45,797

 

The undrawn bank facility relates to the RCF facility.  At 30 September 2022,
£4,000,000 (2021: £nil) of the RCF was drawn, leaving £9.4m undrawn (2021:
£11.1m).

 

 

11.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

                                                                     30 September 2022  30 September 2021
 All figures in £000's                                               (audited)          (audited)
 Cash and cash equivalents                                           36,399             39,460
 Loans and borrowings (excluding lease liabilities) - current        (5,569)            (1,612)
 Loans and borrowings (excluding lease liabilities) - non-current    (78,280)           (94,792)
 Net debt excluding lease liabilities                                (47,450)           (56,944)
 Lease liabilities - current                                         (11,522)           (9,042)
 Lease liabilities - non-current                                     (14,765)           (14,945)
 Net debt                                                            (73,737)           (80,931)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR EADFNAFKAFAA

Recent news on Benchmark Holdings

See all news